Mouse Anti-BCOR Recombinant Antibody (CBYY-0454) (CBMAB-0457-YY)

Name: Mouse Anti-BCOR Recombinant Antibody (CBYY-0454)
SKU: CBMAB-0457-YY
Rating: 5 (1 reviews)

See all BCOR antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

CBYY-0454

Application

Immunogen

Human recombinant protein fragment corresponding to amino acids 384-668 of human BCOR produced in E.coli.

Host Species

Mouse

Specificity

Human, Mouse, Rat

Antibody Isotype

IgG2b

Clonality

Monoclonal

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Application	Note
WB	1:2,000

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Buffer

PBS, pH 7.3, 1% BSA, 50% glycerol

Preservative

0.02% sodium azide

Concentration

1 mg/ml

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

More Infomation

Target

Full Name

BCL6 Corepressor

Introduction

The protein encoded by this gene was identified as an interacting corepressor of BCL6, a POZ/zinc finger transcription repressor that is required for germinal center formation and may influence apoptosis. This protein selectively interacts with the POZ domain of BCL6, but not with eight other POZ proteins. Specific class I and II histone deacetylases (HDACs) have been shown to interact with this protein, which suggests a possible link between the two classes of HDACs. Several transcript variants encoding different isoforMouse have been found for this gene. A pseudogene of this gene is found on chromosome Y.

Entrez Gene ID

54880

UniProt ID

Q6W2J9

Alternative Names

BCL6 Corepressor; BCL-6 Interacting Corepressor; BCL6 Co-Repressor; BCL-6 Corepressor; KIAA1575; MCOPS2; ANOP2; MAA2; BCoR;

Function

Transcriptional corepressor. May specifically inhibit gene expression when recruited to promoter regions by sequence-specific DNA-binding proteins such as BCL6 and MLLT3. This repression may be mediated at least in part by histone deacetylase activities which can associate with this corepressor. Involved in the repression of TFAP2A; impairs binding of BCL6 and KDM2B to TFAP2A promoter regions. Via repression of TFAP2A acts as a negative regulator of osteo-dentiogenic capacity in adult stem cells; the function implies inhibition of methylation on histone H3 'Lys-4' (H3K4me3) and 'Lys-36' (H3K36me2).

Biological Process

Blastocyst hatching Source: Ensembl
Heart development Source: UniProtKB
Histone H2A monoubiquitination Source: UniProtKB
Negative regulation of bone mineralization Source: UniProtKB
Negative regulation of histone H3-K36 methylation Source: UniProtKB
Negative regulation of histone H3-K4 methylation Source: UniProtKB
Negative regulation of tooth mineralization Source: UniProtKB
Negative regulation of transcription, DNA-templated Source: UniProtKB
Negative regulation of transcription by RNA polymerase II Source: UniProtKB
Odontogenesis Source: UniProtKB
Roof of mouth development Source: UniProtKB
Specification of axis polarity Source: UniProtKB

Cellular Location

Nucleus

Involvement in disease

Microphthalmia, syndromic, 2 (MCOPS2): A very rare multiple congenital anomaly syndrome characterized by eye anomalies (congenital cataract, microphthalmia, or secondary glaucoma), facial abnormalities (long narrow face, high nasal bridge, pointed nose with cartilages separated at the tip, cleft palate, or submucous cleft palate), cardiac anomalies (atrial septal defect, ventricular septal defect, or floppy mitral valve) and dental abnormalities (canine radiculomegaly, delayed dentition, oligodontia, persistent primary teeth, or variable root length). Microphthalmia is a disorder of eye formation, ranging from small size of a single eye to complete bilateral absence of ocular tissues (anophthalmia). In many cases, microphthalmia/anophthalmia occurs in association with syndromes that include non-ocular abnormalities.

Ishi, Y., Shimizu, A., Takakuwa, E., Sugiyama, M., Okamoto, M., Motegi, H., ... & Yamaguchi, S. (2021). High‐grade neuroepithelial tumor with BCL6 corepressor‐alteration presenting pathological and radiological calcification: A case report. Pathology International, 71(5), 348-354.

Mardi, L., Tauziède‐Espariat, A., Guillemot, D., Pierron, G., Gigant, P., Mehdi, L., ... & Varlet, P. (2021). Bcor Immunohistochemistry, And Not SATB2, Is A Sensitive And Specific Diagnostic Biomarker For Cns Tumors With BCOR Internal Tandem Duplication. Histopathology.

Li, X., Xu, F., Zhang, Z., Guo, J., He, Q., Song, L. X., ... & Wu, L. Y. (2021). Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome. Clinical epigenetics, 13(1), 1-11.

Manjur, A. K., Lempiäinen, J. K., Malinen, M., Varjosalo, M., Palvimo, J. J., & Niskanen, E. A. (2021). BCOR modulates transcriptional activity of a subset of glucocorticoid receptor target genes involved in cell growth and mobility. The Journal of Steroid Biochemistry and Molecular Biology, 210, 105873.

Eckardt, J. N., Stasik, S., Kramer, M., Röllig, C., Krämer, A., Scholl, S., ... & Middeke, J. M. (2021). Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia. Cancers, 13(9), 2095.

Bremer, J., Kottke, R., Johann, P. D., von Hoff, K., Brazzola, P., Grotzer, M. A., ... & Gerber, N. U. (2020). A single supratentorial high‐grade neuroepithelial tumor with two distinct BCOR mutations, exceptionally long complete remission and survival. Pediatric blood & cancer, 67(7), e28384.

Kotov, J. A., Kotov, D. I., Linehan, J. L., Bardwell, V. J., Gearhart, M. D., & Jenkins, M. K. (2019). BCL6 corepressor contributes to Th17 cell formation by inhibiting Th17 fate suppressors. Journal of Experimental Medicine, 216(6), 1450-1464.

Abuhadra, N., Mukherjee, S., Al-Issa, K., Adema, V., Hirsch, C. M., Advani, A., ... & Nazha, A. (2019). BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes. Leukemia & lymphoma, 60(6), 1587-1590.

Kelly, M. J., So, J., Rogers, A. J., Gregory, G., Li, J., Zethoven, M., ... & Kats, L. M. (2019). Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis. Nature communications, 10(1), 1-14.

Tanaka, T., Nakajima-Takagi, Y., Aoyama, K., Tara, S., Oshima, M., Saraya, A., ... & Iwama, A. (2017). Internal deletion of BCOR reveals a tumor suppressor function for BCOR in T lymphocyte malignancies. Journal of Experimental Medicine, 214(10), 2901-2913.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-BCOR Recombinant Antibody (CBYY-0454)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Related Products

Mouse Anti-BCOR Recombinant Antibody (CBYY-0453) (CAT#: CBMAB-0456-YY)

Rabbit Anti-BCOR Recombinant Antibody (EG379) (CAT#: CBMAB-EN419-LY)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry